tradingkey.logo
tradingkey.logo
Search

Organogenesis Holdings Inc

ORGO
Add to Watchlist
2.370USD
-0.080-3.27%
Close 07-31 16:00ETQuotes delayed by 15 min
304.96MMarket Cap
LossP/E TTM

Organogenesis Holdings Inc

2.370
-0.080-3.27%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-3.27%

5 Days

-0.84%

1 Month

+0.42%

6 Months

-43.97%

Year to Date

-54.25%

1 Year

-47.45%

Key Figures
2.480Open
2.480High
1.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.82%Turnover Ratio
2.450Prev. Close
2.295Low
1.55MTurnover
LossP/E Static
1.25P/B
0.00%Div Yield TTM
0.55%ROA
7.07752wk High
1.94Volume Ratio
-937.00KNet Profit
128.67MShares
-0.1105EPS TTM
1.32Beta
-5.97%ROE
2.04052wk Low
7.55%Amplitude
30.77%Gross Margin
304.96MMarket Cap
-0.31Reward/Risk
3.86%Risk Rate

Key Insights

Organogenesis Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 114 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Organogenesis Holdings Inc's Score

Industry at a Glance

Industry Ranking
114 / 385
Overall Ranking
197 / 4281
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Organogenesis Holdings Inc Highlights

StrengthsRisks
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.25% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 564.17M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -21.45, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.97M shares, decreasing 7.21% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 56.65K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.41.

Analyst Rating

Based on 2 analysts
Hold
Current Rating
3.000
Target Price
+26.58%
Upside Space

Organogenesis Holdings Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 2 analysts
Hold
Current Rating
3.000
Target Price
+26.58%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Organogenesis Holdings Inc
ORGO
2
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(4)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.024
Neutral
RSI(14)
44.055
Neutral
STOCH(KDJ)(9,3,3)
31.948
Sell
ATR(14)
0.146
High Vlolatility
CCI(14)
-90.874
Neutral
Williams %R
70.330
Sell
TRIX(12,20)
0.115
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
2.484
Sell
MA10
2.502
Sell
MA20
2.486
Sell
MA50
2.468
Sell
MA100
2.457
Sell
MA200
3.451
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Organogenesis Holdings Inc Info

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Ticker SymbolORGO
CompanyOrganogenesis Holdings Inc
CEOGillheeney (Gary S)
Websitehttps://investors.organogenesis.com

Shareholders

Shareholders
Shareholders
Proportion
Nussdorf (Glenn H)
9.52%
Morgan Stanley & Co. LLC
8.99%
Ades (Alan A)
8.70%
Erani (Dennis)
7.81%
Soleus Capital Management, L.P.
7.76%
Other
57.23%

FAQs

What is the current price of Organogenesis Holdings Inc (ORGO)?

The current price of Organogenesis Holdings Inc (ORGO) is 2.37.

What is the symbol of Organogenesis Holdings Inc?

The ticker symbol of Organogenesis Holdings Inc is ORGO.

What is the 52-week high of Organogenesis Holdings Inc?

The 52-week high of Organogenesis Holdings Inc is 7.08.

What is the 52-week low of Organogenesis Holdings Inc?

The 52-week low of Organogenesis Holdings Inc is 2.04.

What is the market capitalization of Organogenesis Holdings Inc?

The market capitalization of Organogenesis Holdings Inc is 304.96M.

Is Organogenesis Holdings Inc (ORGO) currently rated as Buy, Hold, or Sell?

According to analysts, Organogenesis Holdings Inc (ORGO) has an overall rating of signal_hold, with a price target of 3.00.

What is the Earnings Per Share (EPS TTM) of Organogenesis Holdings Inc (ORGO)?

The Earnings Per Share (EPS TTM) of Organogenesis Holdings Inc (ORGO) is 0.16.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.